And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

Researchers develop a new platform to improve delivery of oligonucleotide therapies to muscle.

Radiopharmaceuticals are a promising approach to cancer, but some countries are lagging behind. A collaboration hopes to change that.

Why researchers are excited about the potential of extracellular vesicles from umbilical cord-derived stem cells.

We asked three rare disease drug developers about their work, the challenges facing the field, and what they would do with unlimited funds.

A new study reports targeted CRISPR delivery in retinal and neurological disease models – without viral vectors.

The career path of Moncef Slaoui has resulted in billions of doses of lifesaving vaccines. Here he shares his story.

Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.

To shareholders – according to an analysis of financial reports from healthcare companies.

How connecting the data dots can lead to better development and clinical trals.